Cost Effectiveness of a 21-Gene Recurrence Score Assay Versus Canadian Clinical Practice in Post-Menopausal Women with Early-Stage Estrogen or Progesterone-Receptor-Positive, Axillary Lymph-Node Positive Breast Cancer
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost Effectiveness of a 21-Gene Recurrence Score Assay Versus Canadian Clinical Practice in Post-Menopausal Women with Early-Stage Estrogen or Progesterone-Receptor-Positive, Axillary Lymph-Node Positive Breast Cancer
Authors
Keywords
Current Clinical Practice, Recurrence Score, Adjuvant Chemotherapy Regimen, Canadian Setting, Recurrence Score Assay
Journal
PHARMACOECONOMICS
Volume 32, Issue 2, Pages 135-147
Publisher
Springer Nature
Online
2013-11-27
DOI
10.1007/s40273-013-0115-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer
- (2012) Malek B Hannouf et al. BMC CANCER
- Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer
- (2012) Nathan W. D. Lamond et al. BREAST CANCER RESEARCH AND TREATMENT
- Evaluating the efficacy of current clinical practice of adjuvant chemotherapy in postmenopausal women with early-stage, estrogen or progesterone receptor–positive, one-to-three positive axillary lymph node, breast cancer
- (2012) M.B. Hannouf et al. Current Oncology
- Survival and treatment patterns in elderly patients with advanced non-small-cell lung cancer in Manitoba
- (2011) C. L. Baunemann Ott et al. Current Oncology
- Addressing Adoption and Research Design Decisions Simultaneously
- (2011) Claire McKenna et al. MEDICAL DECISION MAKING
- Economic evaluation of the 21-gene signature (Oncotype DX®) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03)
- (2010) Masahide Kondo et al. BREAST CANCER RESEARCH AND TREATMENT
- Effect of 21-Gene Recurrence Score Results on Treatment Recommendations in Patients with Lymph Node-Positive, Estrogen Receptor-Positive Breast Cancer.
- (2010) R. Oratz et al. CANCER RESEARCH
- Radiation treatment waiting times for breast cancer patients in Manitoba, 2001 and 2005
- (2010) A.L. Cooke et al. Current Oncology
- Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20
- (2010) Eleftherios P. Mamounas et al. JOURNAL OF CLINICAL ONCOLOGY
- Prospective Multicenter Study of the Impact of the 21-Gene Recurrence Score Assay on Medical Oncologist and Patient Adjuvant Breast Cancer Treatment Selection
- (2010) Shelly S. Lo et al. JOURNAL OF CLINICAL ONCOLOGY
- Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study
- (2010) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- Cost-Effectiveness Analysis of Recurrence Score-Guided Treatment Using a 21-Gene Assay in Early Breast Cancer
- (2010) D. T. Tsoi et al. ONCOLOGIST
- Economic Implications of 21-Gene Breast Cancer Risk Assay from the Perspective of an Israeli-Managed Health-Care Organization
- (2010) Shmuel H. Klang et al. VALUE IN HEALTH
- How Do Cost-Effectiveness Analyses Inform Reimbursement Decisions for Oncology Medicines in Canada? The Example of Sunitinib for First-Line Treatment of Metastatic Renal Cell Carcinoma
- (2010) Isabelle Chabot et al. VALUE IN HEALTH
- Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
- (2009) R. M. Simon et al. JNCI-Journal of the National Cancer Institute
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
- (2009) Kathy S Albain et al. LANCET ONCOLOGY
- Health Technology Assessment and Primary Data Collection for Reducing Uncertainty in Decision Making
- (2009) Ron Goeree et al. Journal of the American College of Radiology
- The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study
- (2008) Stella Mook et al. BREAST CANCER RESEARCH AND TREATMENT
- Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada
- (2008) Noemi Muszbek et al. CURRENT MEDICAL RESEARCH AND OPINION
- Trial Assessing Individualized Options for Treatment for breast cancer: the TAILORx trial
- (2008) Jo Anne Zujewski et al. Future Oncology
- Docetaxel in Combination With Doxorubicin and Cyclophosphamide As Adjuvant Treatment for Early Node-Positive Breast Cancer: A Cost-Effectiveness and Cost-Utility Analysis
- (2008) Sorrel E. Wolowacz et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Utility of the 21-Gene Assay in Hormone Receptor–Positive Operable Breast Cancer Compared With Classical Clinicopathologic Features
- (2008) Lori J. Goldstein et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started